Akers Biosciences Inc (Nasdaq:AKER) and its proposed merger partner MyMD Pharmaceuticals Inc reported on Thursday the publication of a new study showing the effects of temperature changes on the transmission of SARS-CoV-2, the virus that causes COVID-19.
The study, authored by Adam Kaplin, MD, PhD, chief scientific officer of MyMD Pharmaceuticals, suggests that between the range of 30 to 100 degrees Fahrenheit a one-degree temperature increase is associated with a 1% decrease in the rate of COVID-19 transmission and a one-degree temperature decrease is associated with a 3.7% increase in the rate of transmission. The research was based on 50 Northern Hemisphere countries.
Knowledge of COVID-19 seasonality could feed into local planning for phased reductions, social interventions and preparing for the timing of possible pandemic resurgence during cooler months.
The study has been published in PLOS ONE.
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
Alcami completes third sterile fill-finish line at Research Triangle Park, NC
Black Buffalo partners with Sanova to support regulatory strategy and scientific innovation
Neurocrine Biosciences reveals new chapter in R&D strategy
Nicox completes key data package for NCX 470 NDA submissions
Immusoft's ISP-002 granted US FDA Orphan Drug Designation in MPS II
Orphan Therapeutics Accelerator signs MoU with Fondazione Telethon
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Physiomics secures follow-on UK contract for Phase 2 study support
Ascletis reports positive US Phase I data for oral IL-17 inhibitor ASC50
Dimerix completes adult recruitment in ACTION3 Phase 3 DMX-200 trial
RedHill Biopharma reports positive opaganib data in venetoclax-resistant CLL
Vanda files FDA Biologics License Application for imsidolimab in generalized pustular psoriasis
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
Sobi s Aspaveli marketing authorisation receives positive European regulatory opinion